Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 11/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.36 |
| ▸ | MBTD1 | Q05BQ5 | 6/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.33 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602706 | 0.78 | DYRK1A (0.46) | L3MBTL3L3MBTL1MBTD1LRRK2CALCRL | |
| SCHEMBL4862660 | 0.78 | HRH4 (0.44) | L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL6800821 | 0.76 | CALCRL (0.42) | ALDH1A1KDM4EMAPTRAD52L3MBTL3 | |
| SCHEMBL4862674 | 0.76 | L3MBTL3 (0.38) | ALDH1A1L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL4852839 | 0.74 | L3MBTL3 (0.34) | L3MBTL3L3MBTL1MBTD1TP53BP1CALCRL | |
| SCHEMBL4722263 | 0.73 | CYP3A4 (0.46) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3314168 | 0.73 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1ACACBACACA | |
| SCHEMBL3279492 | 0.73 | L3MBTL3 (0.50) | ALDH1A1KDM4EL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL4860343 | 0.71 | L3MBTL3 (0.41) | ALDH1A1KDM4EL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL4594198 | 0.70 | PDE3B (0.38) | ALDH1A1KDM4EL3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023064195-A1 | CGRP ANTAGONISTS FOR TREATING TRIGEMINAL NEURALGIA | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-04-20 | — | — | WO | claimed |
| WO-2023034467-A2 | CGRP ANTAGONISTS FOR TREATING SKIN CONDITIONS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | claimed |
| US-7314883-B2 | Anti-migraine treatments | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | claimed |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | claimed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | claimed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| WO-2023064195-A1 | CGRP ANTAGONISTS FOR TREATING TRIGEMINAL NEURALGIA | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023034467-A2 | CGRP ANTAGONISTS FOR TREATING SKIN CONDITIONS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | disclosed |
| US-7314883-B2 | Anti-migraine treatments | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | VDAC1, HTR3B, FAAH | ALDH1A1 4339/4885TLR9 4392/4885TLR8 3717/4885 |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BDKRB2, PTGIR, CALCRL | ALDH1A1 2510/4885TLR9 1063/4885TLR8 1015/4885 |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | ALDH1A1 2525/4885TLR9 884/4885TLR8 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.